SeaCrest Wealth Management LLC Reduces Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

SeaCrest Wealth Management LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 6,581 shares of the biopharmaceutical company’s stock after selling 311 shares during the period. SeaCrest Wealth Management LLC’s holdings in Gilead Sciences were worth $737,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Bridgewater Associates LP grew its position in shares of Gilead Sciences by 122.7% during the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company’s stock valued at $42,577,000 after buying an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV lifted its stake in Gilead Sciences by 5.2% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company’s stock valued at $26,750,000 after purchasing an additional 14,009 shares during the last quarter. NatWest Group plc acquired a new stake in Gilead Sciences during the fourth quarter valued at approximately $6,808,000. Empowered Funds LLC raised its holdings in shares of Gilead Sciences by 55.8% during the fourth quarter. Empowered Funds LLC now owns 219,579 shares of the biopharmaceutical company’s stock valued at $20,283,000 after acquiring an additional 78,657 shares during the period. Finally, Ontario Teachers Pension Plan Board increased its stake in Gilead Sciences by 54.6% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company’s stock valued at $3,422,000 after buying an additional 13,086 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.8%

Shares of NASDAQ:GILD opened at $112.46 on Friday. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The company has a 50 day moving average of $105.39 and a 200-day moving average of $101.47. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market cap of $139.89 billion, a price-to-earnings ratio of 303.95, a P/E/G ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. During the same quarter in the previous year, the company earned ($1.32) EPS. Gilead Sciences’s revenue was down .3% on a year-over-year basis. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.81%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s payout ratio is 66.53%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. The trade was a 9.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now directly owns 121,152 shares in the company, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 60,929 shares of company stock valued at $6,748,980. 0.27% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

GILD has been the topic of a number of recent research reports. BMO Capital Markets raised their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price target for the company. Royal Bank of Canada increased their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Finally, DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research report on Thursday, February 13th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.